DORYX
DOXYCYCLINE HYCLATE
Approval overview DORYX is listed in Drugs@FDA under application 050795 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient DOXYCYCLINE HYCLATE Form and strength TABLET, DELAYED RELEASE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor MAYNE PHARMA Submission history Latest submission status date: 2025-03-31 00:00:00.
Structured Monograph
Clinical summary
Approval overview DORYX is listed in Drugs@FDA under application 050795 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient DOXYCYCLINE HYCLATE Form and strength TABLET, DELAYED RELEASE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor MAYNE PHARMA Submission history Latest submission status date: 2025-03-31 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.